{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:24:49Z","timestamp":1760646289049,"version":"3.40.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,2,11]],"date-time":"2015-02-11T00:00:00Z","timestamp":1423612800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s00228-014-1789-4","type":"journal-article","created":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T03:29:21Z","timestamp":1423538961000},"page":"303-311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy"],"prefix":"10.1007","volume":"71","author":[{"given":"Ellen G. J.","family":"Hulskotte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Douglas","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwa-Ping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn R.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"O\u2019Mara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan R.","family":"Butterton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,11]]},"reference":[{"key":"1789_CR1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"B Bacon","year":"2011","unstructured":"Bacon B, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Burroughs M, Brass CA, Albrecht JK, Esteban R (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207\u20131217","journal-title":"N Engl J Med"},{"key":"1789_CR2","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy R, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195\u20131206","journal-title":"N Engl J Med"},{"key":"1789_CR3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335\u20131374","journal-title":"Hepatology"},{"key":"1789_CR4","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","volume":"41","author":"CB Eap","year":"2002","unstructured":"Eap CB, Buclin T, Baumann P (2002) Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 41:1153\u20131193","journal-title":"Clin Pharmacokinet"},{"key":"1789_CR5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3109\/00952990.2011.568081","volume":"37","author":"RD Bruce","year":"2011","unstructured":"Bruce RD, Moody DE, Fang WB, Chodkowski D, Andrews L, Friedland GH (2011) Tipranavir\/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine\/naloxone. Am J Drug Alcohol Abuse 37:224\u2013228","journal-title":"Am J Drug Alcohol Abuse"},{"key":"1789_CR6","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.110.036996","volume":"39","author":"A Ghosal","year":"2010","unstructured":"Ghosal A, Yuan Y, Tong W, Su A, Gu C, Chowdhury SK, Kishnani NS (2010) Characterization of human liver enzymes involved in the biotransformation of boceprevir, a HCV protease inhibitor. Drug Metab Pharmacokinet 39:510\u2013521. doi: 10.1124\/dmd.110.036996","journal-title":"Drug Metab Pharmacokinet"},{"key":"1789_CR7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.qai.0000219769.89679.ec","volume":"41","author":"RD Bruce","year":"2006","unstructured":"Bruce RD, Altice FL, Gourevitch MN, Friedland GH (2006) Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 41:563\u2013572","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1789_CR8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","volume":"44","author":"A Elkader","year":"2005","unstructured":"Elkader A, Sproule B (2005) Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 44:661\u2013680","journal-title":"Clin Pharmacokinet"},{"key":"1789_CR9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/jat\/33.8.409","volume":"33","author":"WB Fang","year":"2009","unstructured":"Fang WB, Chang Y, Cance-Katz EF, Moody DE (2009) Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. J Anal Toxicol 33:409\u2013417","journal-title":"J Anal Toxicol"},{"key":"1789_CR10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.drugalcdep.2009.07.007","volume":"105","author":"RD Bruce","year":"2009","unstructured":"Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH (2009) Pharmacokinetic interactions between buprenorphine\/naloxone and tipranavir\/ritonavir in HIV-negative subjects chronically receiving buprenorphine\/naloxone. Drug Alcohol Depend 105:234\u2013239","journal-title":"Drug Alcohol Depend"},{"key":"1789_CR11","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1128\/AAC.02347-12","volume":"57","author":"EG Hulskotte","year":"2013","unstructured":"Hulskotte EG, Feng HP, Xuan F, Gupta S, van Zutven MG, O\u2019Mara E, Wagner JA, Butterton JR (2013) Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob Agents Chemother 57:2582\u20132588","journal-title":"Antimicrob Agents Chemother"},{"key":"1789_CR12","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/hep.25831","volume":"56","author":"E Hulskotte","year":"2012","unstructured":"Hulskotte E, Gupta S, Xuan F, van Zutven M, O\u2019Mara E, Feng HP, Wagner J, Butterton J (2012) Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 56:1622\u20131630","journal-title":"Hepatology"},{"key":"1789_CR13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.20279","volume":"40","author":"S Mauss","year":"2004","unstructured":"Mauss S, Berger F, Goelz J, Jacob B, Schmutz G (2004) A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 40:120\u2013124","journal-title":"Hepatology"},{"key":"1789_CR14","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","volume":"50","author":"A Ferrari","year":"2004","unstructured":"Ferrari A, Coccia CPR, Bertolini A, Sternieri E (2004) Methadone\u2014metabolism, pharmacokinetics and interactions. Pharmacol Res 50:551\u2013559","journal-title":"Pharmacol Res"},{"key":"1789_CR15","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1128\/AAC.02262-12","volume":"57","author":"R Heeswijk van","year":"2013","unstructured":"van Heeswijk R, Vandevoorde A, Verboven P, Boogaerts G, De Paepe E, van Solingen-Ristea R, Garg V, Beumont M (2013) The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. Antimicrob Agents Chemother 57:2304\u20132309","journal-title":"Antimicrob Agents Chemother"},{"key":"1789_CR16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1586\/ecp.13.18","volume":"6","author":"RD Bruce","year":"2013","unstructured":"Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH (2013) A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol 6:249\u2013269","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1789_CR17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/187231209788654117","volume":"3","author":"Y Chang","year":"2009","unstructured":"Chang Y, Moody DE (2009) Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett 3:101\u2013107","journal-title":"Drug Metab Lett"},{"key":"1789_CR18","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1128\/AAC.01229-13","volume":"57","author":"RD Bruce","year":"2013","unstructured":"Bruce RD, Winkle P, Custodio JM, Wei X, Rhee MS, Kearney BP, Ramanathan S, Friedland GH (2013) Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. Antimicrob Agents Chemother 57:6154\u20136157","journal-title":"Antimicrob Agents Chemother"},{"key":"1789_CR19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clpt.2004.09.008","volume":"77","author":"M Sulkowski","year":"2005","unstructured":"Sulkowski M, Wright T, Rossi S, Arora S, Lamb M, Wang K, Gries JM, Yalamanchili S (2005) Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin Pharmacol Ther 77:214\u2013224","journal-title":"Clin Pharmacol Ther"},{"key":"1789_CR20","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1111\/j.1572-0241.2008.02065.x","volume":"103","author":"HL Bonkovsky","year":"2008","unstructured":"Bonkovsky HL, Tice AD, Yapp RG, Bodenheimer HC Jr, Monto A, Rossi SJ, Sulkowski MS (2008) Efficacy and safety of peginterferon alfa-2a\/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol 103:2757\u20132765","journal-title":"Am J Gastroenterol"},{"key":"1789_CR21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.clinthera.2007.01.009","volume":"29","author":"SI Berk","year":"2007","unstructured":"Berk SI, Litwin AH, Arnsten JH, Du E, Soloway I, Gourevitch MN (2007) Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment. Clin Ther 29:131\u2013138","journal-title":"Clin Ther"},{"key":"1789_CR22","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0022-3565(24)35227-9","volume":"291","author":"NL Benowitz","year":"1999","unstructured":"Benowitz NL, Perez-Stable EJ, Fong I, Modin G, Herrera B, Jacob P III (1999) Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 291:1196\u20131203","journal-title":"J Pharmacol Exp Ther"},{"key":"1789_CR23","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1124\/dmd.112.049668","volume":"41","author":"X Chu","year":"2013","unstructured":"Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G, Green MD, Kuo Y, Liang Y, Maciolek CM, Palamanda J, Evers R, Prueksaritanont T (2013) In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos 41:668\u2013681","journal-title":"Drug Metab Dispos"},{"key":"1789_CR24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/cid\/cis824","volume":"56","author":"CT Kanter de","year":"2013","unstructured":"de Kanter CT, Blonk MI, Colbers AP, Schouwenberg BJ, Burger DM (2013) Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis 56:300\u2013306","journal-title":"Clin Infect Dis"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1789-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-014-1789-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1789-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T19:10:31Z","timestamp":1747595431000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-014-1789-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,11]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["1789"],"URL":"https:\/\/doi.org\/10.1007\/s00228-014-1789-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2015,2,11]]}}}